Publications by authors named "A I Greenspan"
Nontransformed cells form heterotypic cadherin junctions with adjacent transformed cells to inhibit tumor cell growth and motility. Transformed cells must override this form of growth control, called "contact normalization", to invade and metastasize during cancer progression. Heterocellular cadherin junctions between transformed and nontransformed cells are needed for this process.
View Article and Find Full Text PDFBackground: Systemic inequities may place people with disabilities at higher risk of severe coronavirus disease 2019 (COVID-19) illness or lower likelihood to be discharged home after hospitalization. We examined whether severity of COVID-19 hospitalization outcomes and disposition differ by disability status and disability type.
Methods: In a retrospective analysis of April 2020-November 2021 hospital-based administrative data among 745 375 people hospitalized with COVID-19 from 866 US hospitals, people with disabilities (n = 120 360) were identified via ICD-10-CM codes.
Up to 70 million people around the world suffer from rheumatoid arthritis. Current treatment options have varied efficacy and can cause unwanted side effects. New approaches are needed to treat this condition.
View Article and Find Full Text PDFArticle Synopsis
- A phase 3b trial named SEAVUE was conducted to compare the effectiveness and safety of monotherapy using ustekinumab versus adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.
- A total of 386 eligible patients were randomly assigned to receive either ustekinumab or adalimumab, with the primary goal being to determine the clinical remission rates after 52 weeks of treatment.
- Results showed that 15% of patients in the ustekinumab group and 24% in the adalimumab group discontinued treatment before 52 weeks, but no significant difference was found between the two medications in terms of efficacy or safety.
Objective: Evaluate tolerability and effectiveness of golimumab-IV versus infliximab in patients with rheumatoid arthritis (RA) in a real-world setting.
Methods: AWARE, a prospective, real-world, pragmatic, observational, multicenter, phase 4 study, enrolled RA patients when initiating golimumab-IV or infliximab. Treatment decisions were made by the treating rheumatologist.